[Corticosteroid therapy for sarcoidosis].
Even after 50-year experience of corticosteroid therapy for sarcoidosis, no definite protocol nor indication criteria have been established for the treatment of sarcoidosis. The high incidence of spontaneous remission, the high rate of relapse after steroid-induced remission, absence of sensitive marker to predict the disease progression, lack of evidences whether corticosteroids alter the natural history of sarcoidosis, and the adverse effects of long-term corticosteroid therapy have made the indication controversial. As a consensus statement at present, the most common indication of systemic corticosteroid therapy for sarcoidosis is systemic and symptomatic diseases including cardiac disease, neurologic disease, eye disease refractory to topical therapy, and hypercalcemia, as well as the progressive pulmonary disease.
Hiyama
Keiko
K
Department of Molecular and Internal Medicine, Division of Clinical Medical Science, Programs for Applied Biomedicine, Hiroshima University Graduate School of Biomedical Sciences.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D032921:Consensus; D019317:Evidence-Based Medicine; D006801:Humans; D007564:Japan; D018579:Patient Selection; D012008:Recurrence; D012074:Remission Induction; D012507:Sarcoidosis / Q000188:drug therapy*; D013256:Steroids
D000893:Anti-Inflammatory Agents; D013256:Steroids